Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ) has issued an update.
Sinco Pharmaceuticals Holdings Limited has announced the results of its internal control remediation following an interest-free loan granted to Mr. Huang Xiangbin, which breached the Listing Rules. The company has taken corrective actions by revising its Connected Transaction Management Measures and conducting training for its directors and senior management to ensure compliance with regulatory requirements. These efforts aim to strengthen corporate governance and restore stakeholder confidence.
The most recent analyst rating on (HK:6833) stock is a Hold with a HK$0.19 price target. To see the full list of analyst forecasts on Sinco Pharmaceuticals Holdings Ltd. stock, see the HK:6833 Stock Forecast page.
More about Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Limited is a company incorporated under the laws of the Cayman Islands, operating in the pharmaceutical industry. The company is listed on the Stock Exchange of Hong Kong and is involved in the development and distribution of pharmaceutical products.
Average Trading Volume: 221,951
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$386.2M
For detailed information about 6833 stock, go to TipRanks’ Stock Analysis page.